Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
481-500 of 1,782 trials

Chronic Inflammatory Demyelinating Polyneuropathy: Riliprubart Study

We are testing the new medication riliprubart in people with CIDP who haven't found relief from usual treatments. The study will help us understand its effects on disability, quality of life, and safety.

Chronic Inflammatory Demyelinating Polyneuropathy6-12 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementNeurology

Severe Hemophilia A: Continued Access to Efanesoctocog Alfa

We are providing ongoing treatment access for patients with severe hemophilia A who completed a previous trial with efanesoctocog alfa. The study aims to gather more information on its safety and effectiveness in preventing and treating bleeding episodes.

Haemophilia AConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Teicoplanin for Infection Prevention in Pediatric AML

We are studying whether teicoplanin can help prevent serious infections in children newly diagnosed with acute myeloid leukemia. This trial will assess its safety and effectiveness during their treatment.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesOncology

Propranolol for Anxiety in Pancreatic Cancer Surgery

We are studying whether propranolol can help reduce anxiety in patients undergoing surgery for pancreatic cancer and if it affects tumor-related changes. This trial will compare the effects of propranolol to a placebo in a small group of participants.

Pancreatic Cancer>2 yearsEfficacy phase (II)Standard MedicinesGastroenterologyInternal MedicineOncology

Mycobacterium abscessus: Optimizing Lung Disease Treatment

We are studying the best treatment options for lung disease caused by Mycobacterium abscessus. Our goal is to see how well these treatments clear the infection and how well patients tolerate them.

Mycobacterium Abscessus Infection1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesPulmonology

Large-Cell Neuroendocrine Carcinomas: Durvalumab Combination Therapy

We are studying a new treatment combining durvalumab with etoposide and platinum for patients with advanced large-cell neuroendocrine carcinomas of the lung. The goal is to evaluate its effectiveness and safety compared to standard treatments.

Large-Cell Neuroendocrine Carcinoma of the LungLocally Advanced or Metastatic Lung Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Early Rectal Cancer: FARE Trial with [68Ga]Ga-FAPI-46 PET/CT

We are studying a new imaging method to detect lymph node spread in early rectal cancer patients. This trial aims to see if it provides more accurate results than standard imaging techniques.

Rectal Cancer≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInfectious DiseasesInternal MedicineOtolaryngology

Liver Transplant: Single vs. Twice Daily Immunosuppressive Doses

We are studying whether a single daily dose of immunosuppressive medication is as effective as a twice-daily dose for liver transplant recipients. This trial also compares two different formulations of tacrolimus to see which works better.

Transplantation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHepatologyInternal Medicine

Schizophrenia: Intensified Treatment Study

We are investigating whether a six-week intensified medication plan helps individuals with schizophrenia who didn't respond to their first treatment. The study looks at changes in symptoms, functioning, and overall well-being compared to standard care.

Schizophrenia and Related Disorders≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Alzheimer's Disease in Down Syndrome: Sleep and Temperature Study

We are examining how sleep disorders and body temperature changes may indicate the progression of Alzheimer's disease in people with Down syndrome. This research could help identify early signs of the disease.

Down SyndromeAlzheimer's Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNeurologyPsychiatry

Major Depressive Disorder: New Treatment Approach

We are studying whether a six-week intensified medication treatment helps people with major depressive disorder who didn't respond to their first treatment. The goal is to see if this new approach improves symptoms and overall well-being compared to standard care.

Major Depressive Disorder≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Niraparib: Long-Term Safety Study for Cancer Patients

We are evaluating the long-term safety and tolerability of niraparib for patients who have previously completed a study and are deemed to benefit from continued treatment. This study helps us understand how well the medication can be tolerated over time.

Advanced Ovarian, Breast, or Prostate CancerEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Breast Cancer: Lower Dose of CDK 4/6-Inhibitors

We are studying whether a lower initial dose of a cancer medication is effective for older breast cancer patients compared to the standard dose. This trial aims to improve treatment outcomes and quality of life for vulnerable patients.

Advanced Breast Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteGastroenterologyGynecology and ObstetricsOncology

Giant Cell Arteritis: Etanercept vs. Methotrexate

We are comparing two treatments, etanercept and methotrexate, to see which is more effective for patients with giant cell arteritis. The goal is to find out which treatment helps achieve remission and prevents complications better.

Giant Cell ArteritisEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInfectious DiseasesRheumatology

Crohn's Disease: Dual Biological Therapy Study

We are evaluating whether a combination of medications can help patients with Crohn's disease who haven't responded to previous treatments. The study compares single therapies to combination therapies to find the most effective approach.

Crohn's DiseaseEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInfectious Diseases

Ulcerative Colitis: Dual Therapy Study

We are comparing single and combination therapies for patients with ulcerative colitis who didn't respond to previous treatment. The goal is to see which option may help achieve better remission and quality of life.

Ulcerative Colitis>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Dapagliflozin for Heart Protection in Breast Cancer Patients

We are studying whether dapagliflozin can help prevent heart problems in breast cancer patients receiving chemotherapy. This trial compares its effects to a placebo over 12 months.

Secondary CardiomyopathyInvasive Breast Cancer3-6 monthsConfirmation phase (III)Standard MedicinesCardiologyOncology

Metastatic Colorectal Cancer: Atezolizumab with FOLFOXIRI

We are studying whether adding Atezolizumab to standard treatment helps patients with unresectable metastatic colorectal cancer live longer without disease progression. The trial also looks at the safety and quality of life for participants.

Metastatic Colorectal Cancer3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Rheumatoid Arthritis: Rituximab Tapering Strategies

We are studying different ways to reduce rituximab doses in patients with rheumatoid arthritis. The goal is to find the best method to lower disease impact and activity.

Rheumatoid Arthritis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Graft-Versus-Host Disease Prevention in Elderly Cancer Patients

We are studying whether a low dose of a specific medication can help prevent complications in elderly patients with blood cancers receiving stem cell transplants. This trial aims to improve recovery and overall outcomes after the transplant.

Blood Cancers>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology